Table 1. Descriptive covariates, showing clinicopathological, treatment and lifestyle features of patients from which the samples were taken as well as the results that were obtained for biomarker measurement.
|
NSR (n=60) |
REC (n=52) |
Total subjects (n=112) |
|||||
|---|---|---|---|---|---|---|---|
| Mean (s.d.) | Range | Mean (s.d.) | Range | Mean (s.d.) | Range | ||
| Age at diagnosis | * | 52.19 (9.29) | 33.45–71.76 | 53.21 (11.51) | 31.80–74.50 | 52.66 (10.29) | 31.80–74.50 |
| Tumour size (mm) | * | 24.14 (15.53) | 2–70 | 28.54 (20.51) | 5–110 | 26.15 (18.02) | 2–110 |
| Height (m) | 1.63 (0.06) | 1.50–1.79 | 1.63 (0.07) | 1.47–1.80 | 1.63 (0.06) | 1.47–1.80 | |
| Weight at diagnosis (kg) | 72.41 (13.60) | 51.5–114.0 | 69.64 (14.20) | 47.7–127.0 | 71.12 (13.60) | 47.7–127.0 | |
| BMI at diagnosis | 27.31 (4.81) | 17.61–39.02 | 26.14 (5.02) | 17.95–43.84 | 26.76 (4.92) | 17.61–43.84 | |
| CDH5 (ng ml−1) | 9.51 (9.84) | 0.12–43.03 | 13.77 (13.93) | 0.03–79.10 | 11.49 (12.05) | 0.03–79.10 | |
| HPA (AU ml−1) | 151.98 (143.56) | 3.22–611.27 | 144.64 (137.34) | 11.26–839.78 | 148.58 (140.11) | 3.22–839.78 | |
| CDH5/HPA ratio (ng AU−1) | 0.085 (0.067) | 0.003–0.296 | 0.114 (0.083) | 0.001–0.586 | 0.098 (0.076) | 0.001–0.586 | |
| n | % | n | % | n | % | ||
| Grade 1 | 3 | 5.0 | 2 | 3.8 | 5 | 4.5 | |
| Grade 2 | * | 22 | 36.7 | 20 | 38.5 | 42 | 37.5 |
| Grade 3 | 35 | 58.3 | 30 | 57.7 | 65 | 58.0 | |
| Lymph node -ve | 26 | 43.3 | 22 | 42.3 | 48 | 42.9 | |
| Lymph node 1–3 +ve | * | 21 | 35.0 | 13 | 25.0 | 34 | 30.4 |
| Lymph node >3 +ve | 13 | 21.7 | 17 | 32.7 | 30 | 26.8 | |
| ER positive | 44 | 73.3 | 32 | 61.5 | 76 | 67.9 | |
| ER negative | * | 16 | 26.7 | 20 | 38.5 | 36 | 32.1 |
| PR positive | 20 | 33.3 | 18 | 34.6 | 38 | 33.9 | |
| PR negative | * | 22 | 36.7 | 16 | 30.8 | 38 | 33.9 |
| HER2 positive | 13 | 21.7 | 15 | 28.8 | 28 | 25.0 | |
| HER2 negative | * | 37 | 61.7 | 26 | 50.0 | 63 | 56.3 |
| Vascular Invasion | 25 | 41.7 | 29 | 55.8 | 54 | 48.2 | |
| No vascular invasion | 33 | 55.0 | 23 | 44.2 | 56 | 50.0 | |
| Local recurrence | 1 | 1.7 | 5 | 9.6 | 6 | 5.4 | |
| No local recurrence | 59 | 98.3 | 47 | 90.4 | 106 | 94.6 | |
| Pre-menopausal | 14 | 23.3 | 15 | 28.8 | 29 | 25.9 | |
| Peri-menopausal | 15 | 25.0 | 11 | 21.2 | 26 | 23.2 | |
| Post-menopausal | 31 | 51.7 | 25 | 48.1 | 56 | 50.0 | |
| Blood group A | 26 | 43.3 | 20 | 38.5 | 46 | 41.1 | |
| Blood group B | 8 | 13.3 | 1 | 1.9 | 9 | 8.0 | |
| Blood group AB | 6 | 10.0 | 4 | 7.7 | 10 | 8.9 | |
| Blood group O | 20 | 33.3 | 27 | 51.9 | 47 | 42.0 | |
| Neoadjuvant chemotherapy | 3 | 5.0 | 9 | 17.3 | 12 | 10.7 | |
| No neoadjuvant chemotherapy | 57 | 95.0 | 43 | 82.7 | 100 | 89.3 | |
| Adjuvant Chemotherapy | 44 | 73.3 | 34 | 65.4 | 78 | 69.6 | |
| No adjuvant chemotherapy | 16 | 26.7 | 18 | 34.6 | 34 | 30.4 | |
| Tamoxifen | 29 | 48.3 | 21 | 40.4 | 50 | 44.6 | |
| Arimidex/anastrozole | 11 | 18.3 | 8 | 15.4 | 19 | 17.0 | |
| Herceptin | 7 | 11.7 | 5 | 9.6 | 12 | 10.7 | |
| Other | 6 | 10.1 | 4 | 7.6 | 10 | 9.0 | |
| None | 7 | 11.7 | 14 | 26.9 | 21 | 18.8 | |
| Current smoker | 3 | 5.0 | 2 | 3.8 | 5 | 4.5 | |
| Ex-smoker | 20 | 33.3 | 14 | 26.9 | 34 | 30.4 | |
| Non-smoker | 36 | 60.0 | 31 | 59.6 | 67 | 59.8 | |
| Current drinker | 50 | 83.3 | 37 | 71.2 | 87 | 77.7 | |
| Former drinker | 2 | 3.3 | 3 | 5.8 | 5 | 4.5 | |
| Non-drinker | 7 | 11.7 | 7 | 13.5 | 14 | 12.5 | |
Abbreviations: BMI=body mass index; CDH5=cadherin-5; ER=oestrogen receptor; HER2=receptor tyrosine-protein kinase erbB-2; HPA=helix pomatia agglutinin; NSR=no sign of recurrence; PR=progesterone receptor; REC=recurrent breast cancer. NSR and REC patients were matched according to asterisked categories. Where percentages do not total 100, the absent data was not collected and/or is unknown.